Compare Ishares Msci Italy ETF (EWI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs Sanofi SA — how do they compare? Ishares Msci Italy ETF trades at $56.17 (market cap $1.14B), while Sanofi SA trades at $40.12 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 83.5× Ishares Msci Italy ETF's market cap, and Sanofi SA pays a 6.01% dividend while Ishares Msci Italy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Italy ETF for 52 Days and Sanofi SA for 94 Days on average.
| EWI | SNY | |
|---|---|---|
Market Cap | $1.14B | $95.18B |
Volume | 2,377,947 | 2,995,646 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $52.34 |
52-Week Low | $50.31 | $39.51 |
Typical Hold Time | 52 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWI, the iShares MSCI Italy ETF, trades at $56.35, down 2.74% on the day, reflecting a bearish technical outlook with all moving averages signaling sell. The ETF provides exposure to Italian financials, utilities, and industrials, benefiting from EU recovery investments and sector consolidation. Recent news highlights ECB rate hikes and eurozone economic concerns, with energy-driven inflation posing headwinds.
The outlook remains cautious due to macroeconomic pressures from rising interest rates and inflation, though structural investments in Italian infrastructure offer long-term potential. Key risks include eurozone volatility and energy price shocks, while technical indicators suggest near-term weakness. Investors should weigh sector-specific strengths against broader market sentiment.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
